BE555319A - - Google Patents

Info

Publication number
BE555319A
BE555319A BE555319DA BE555319A BE 555319 A BE555319 A BE 555319A BE 555319D A BE555319D A BE 555319DA BE 555319 A BE555319 A BE 555319A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of BE555319A publication Critical patent/BE555319A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BE555319D 1956-03-21 BE555319A (Direct)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US572788A US2868691A (en) 1956-03-21 1956-03-21 Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine

Publications (1)

Publication Number Publication Date
BE555319A true BE555319A (Direct) 1900-01-01

Family

ID=24289356

Family Applications (1)

Application Number Title Priority Date Filing Date
BE555319D BE555319A (Direct) 1956-03-21

Country Status (3)

Country Link
US (1) US2868691A (Direct)
BE (1) BE555319A (Direct)
GB (1) GB830426A (Direct)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3051621A (en) * 1959-10-22 1962-08-28 Grove Lab Inc Gel composition, pressurized container with same, and method of preparation
US3050443A (en) * 1960-02-16 1962-08-21 James F Schuyler Headache remedy containing ammonia
US3039928A (en) * 1960-03-17 1962-06-19 Abbott Lab Stable aqueous isoproteronol compositions
NL262354A (Direct) * 1960-03-17
US3088874A (en) * 1960-05-23 1963-05-07 Union Carbide Corp Powder aerosol
US3282781A (en) * 1960-11-25 1966-11-01 Merck & Co Inc Inhalant compositions
BE632504A (Direct) * 1962-05-24
US3169095A (en) * 1962-10-30 1965-02-09 Rexall Drug Chemical Self-propelling powder-dispensing compositions
NL302251A (Direct) * 1963-01-28 1965-10-11
US3710782A (en) * 1969-10-01 1973-01-16 Hauser Res And Eng Co Method of treating human skin with a composition for electromedical applications
FI770215A7 (Direct) * 1976-01-30 1977-07-31 Fisons Ltd
AU522792B2 (en) * 1977-07-19 1982-06-24 Fisons Plc Pressure pack formulation
US4352789A (en) * 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
US4655231A (en) * 1984-01-09 1987-04-07 Advanced Tobacco Products, Inc. Snuff and preparation thereof
US4576949A (en) * 1984-05-07 1986-03-18 The Upjohn Company Use of 5,6,7,8-tetrahydroquinolines and 5,6-dihydropyrindines as leukotriene and lipoxygenase inhibitors and the novel 3-substituted compounds therein
EP0213108A3 (de) * 1985-06-26 1987-07-15 Kurt Dr. Burghart Pharmazeutische Zubereitung mit einem Antihypotonikum als wirksames Mittel
JPH0645538B2 (ja) * 1987-09-30 1994-06-15 日本化薬株式会社 ニトログリセリンスプレー剤
FR2625677A1 (fr) * 1988-01-07 1989-07-13 Cosnier Alain Composition medicamenteuse destinee a etre administree sous forme d'aerosol
DE68915203T2 (de) * 1988-03-22 1994-09-22 Fisons Plc, Ipswich, Suffolk Pharmazeutische Mischungen.
US5776434A (en) 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4003270A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5175152A (en) * 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5785952A (en) * 1990-11-09 1998-07-28 Glaxo Group Limited Aerosol medicament formulation having a surface coating of surfactant
US5919435A (en) * 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
DE69207409D1 (de) 1991-06-10 1996-02-15 Schering Corp Fluorchlorkohlenwasserstoffreie aerosolformulierungen
US5234933A (en) * 1991-10-31 1993-08-10 Board Of Governors Of Wayne State University And Vanderbilt University Cyclic hydroxamic acids
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
JP3280974B2 (ja) * 1991-12-12 2002-05-13 グラクソ、グループ、リミテッド 医 薬
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
JP3026841B2 (ja) * 1991-12-12 2000-03-27 グラクソ、グループ、リミテッド 医 薬
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
ES2159678T3 (es) * 1991-12-18 2001-10-16 Minnesota Mining & Mfg Formulaciones de aerosol en suspension.
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
WO1994013262A1 (en) * 1992-12-09 1994-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. Stabilized medicinal aerosol solution formulations
TW248552B (Direct) * 1993-06-01 1995-06-01 Onoda Yakuhin Kogyo Kk
EP0640609A1 (en) * 1993-08-24 1995-03-01 Ono Pharmaceutical Co., Ltd. Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
ES2115887T3 (es) * 1993-12-03 1998-07-01 Ono Pharmaceutical Co Derivados de amidinofenoles con actividad de inhibidores de fosfolipasa a2.
EP0735884B1 (en) * 1993-12-20 2000-04-26 Minnesota Mining And Manufacturing Company Flunisolide aerosol formulations
ATE178589T1 (de) 1994-09-20 1999-04-15 Ono Pharmaceutical Co Amidinophenol-derivate als protease-hemmende verbindungen
US5840213A (en) * 1995-04-28 1998-11-24 Great Lakes Chemical Corporation Uses of heptafluoropropane
US5679287A (en) * 1995-04-28 1997-10-21 Great Lakes Chemical Corporation Uses of heptafluoropropane
KR980009238A (ko) 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
ES2185750T3 (es) * 1995-08-08 2003-05-01 Ono Pharmaceutical Co Derivados de acido hidroxamico utiles para la inhibicion gelatinasa.
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5861268A (en) * 1996-05-23 1999-01-19 Biomide Investment Limited Partnership Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
ES2178817T3 (es) 1997-02-05 2003-01-01 Jago Res Ag Formulaciones medicinales de aerosol.
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US7153866B1 (en) * 1997-05-27 2006-12-26 The United States Of America As Represented By The Department Of Health And Human Services Use of tempol for the treatment of Li-Fraumeni syndrome and ataxia telangiectasia
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
JPH11187882A (ja) 1997-12-26 1999-07-13 Ono Pharmaceut Co Ltd 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｃＤＮＡ、そのｃＤＮＡからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのペプチドまたは抗体を含有する薬学的組成物
CN1158996C (zh) 1998-07-24 2004-07-28 杰格研究股份公司 药用气溶胶制剂
ES2193726T3 (es) 1998-08-04 2003-11-01 Jago Res Ag Formulaciones de aerosol medicinales.
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
TWI313608B (en) 2001-07-23 2009-08-21 Ono Pharmaceutical Co Lower bone mass treating agent containing er4 agonist as active ingredient
WO2003070707A1 (en) 2002-02-19 2003-08-28 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
EP1534235B1 (en) * 2002-06-25 2016-07-27 Acrux DDS Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
TW200410688A (en) 2002-06-26 2004-07-01 Ono Pharmaceutical Co Therapeutics for diseases from vasoconstriction or vasodilatation
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
AU2003241836A1 (en) 2002-10-03 2004-04-23 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
EP1563845A4 (en) * 2002-10-10 2008-02-20 Univ Kyoto REMEDIES FOR ALLERGIC DISEASES
ES2393321T3 (es) 2002-10-10 2012-12-20 Ono Pharmaceutical Co., Ltd. Promotores de la producción de factores de reparación endógenos
EP2270051B1 (en) 2003-01-23 2019-05-15 Ono Pharmaceutical Co., Ltd. Antibody specific for human PD-1 and CD3
CA2517888C (en) 2003-03-14 2012-05-01 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
WO2004092169A1 (ja) 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
US20050107306A1 (en) * 2003-05-16 2005-05-19 Barr Philip J. Treatment of respiratory disease associated with matrix metalloproteases by inhalation of synthetic matrix metalloprotease inhibitors
WO2006031210A1 (en) 2003-05-29 2006-03-23 Board Of Regents, The University Of Texas Systems Jabi as a prognostic marker and a therapeutic target for human cancer
EP1661580B1 (en) 2003-07-25 2014-01-08 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
CA2537093C (en) 2003-08-29 2013-11-12 Ono Pharmaceutical Co., Ltd. Compound capable of binding s1p receptor and pharmaceutical use thereof
ES2425746T3 (es) 2003-09-01 2013-10-17 Ono Pharmaceutical Co., Ltd. Compuesto cíclico condensado y uso del mismo
CA2538237A1 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
CA2542530A1 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical aerosol compositions
US7511159B2 (en) 2003-12-25 2009-03-31 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
WO2006004646A1 (en) * 2004-06-28 2006-01-12 Nektar Therapeutics Aerosol formulation comprising nicotine salt
EP1806147B1 (en) 2004-10-21 2014-04-30 Ono Pharmaceutical Co., Ltd. Use of immunesuppressant receptor
PT1814538E (pt) * 2004-11-24 2009-11-10 Alcon Inc Método de aplicar uma aspersão nasal
WO2006084041A2 (en) 2005-02-02 2006-08-10 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating or preventing diabetes
ES2685315T3 (es) 2005-05-18 2018-10-08 Horizon Orphan Llc Fluoroquinolonas en aerosol y sus usos
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CA2611496C (en) 2005-06-17 2015-07-28 Wisconsin Alumni Research Foundation Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
DK1942108T3 (da) 2005-10-28 2013-12-09 Ono Pharmaceutical Co Forbindelse indeholdende basisk gruppe samt anvendelse deraf
US20090281120A1 (en) 2005-12-12 2009-11-12 Ono Pharmaceutical Co., Ltd Bicyclic heterocyclic compound
EP1961754A4 (en) 2005-12-15 2009-11-11 Ono Pharmaceutical Co BICYCLIC HETEROCYCLIC COMPOUND
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
EP2425819A1 (en) * 2007-02-11 2012-03-07 MAP Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
DE102008007198A1 (de) 2008-02-01 2009-08-13 Infectopharm Arzneimittel Und Consilium Gmbh Oral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften
PL2346509T3 (pl) 2008-10-07 2021-03-08 Horizon Orphan Llc Lewofloksacyna w postaci aerozolu dla zmniejszania stanu zapalnego płuc
CA2739897C (en) 2008-10-07 2017-10-03 Mpex Pharmaceuticals, Inc. Aerosol fluoroquinolone formulations for improved pharmacokinetics
TWI469965B (zh) 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
JP5621771B2 (ja) 2009-06-17 2014-11-12 小野薬品工業株式会社 新規なイミダゾピリジン化合物
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
AU2010289326B2 (en) 2009-09-04 2015-09-24 Horizon Therapeutics U.S. Holding Llc Use of aerosolized levofloxacin for treating cystic fibrosis
WO2011066537A1 (en) 2009-11-30 2011-06-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
MX2012014596A (es) 2010-06-21 2013-02-21 Ono Pharmaceutical Co Nuevas formas cristalinas de acido 4,4`-[4-fluoro-7-7{4-[4-(3-fluo ro-2-metilfenil)butoxi]fenil}etinil)-2-metil-1h-indol-1, 3-diil]dibutanoico, acido 4, 4´-[2-metil-7-({4-[4-(pentafluorofeni l)butoxi}fenil}etil)-1h-indol-1, 3-diil]-dibutanoico, y acido 4, 4´-[4-fluoro-2-metil-7-({4-[4-(2, 3, 4, 6-tetrafluorofenil)butoxi] fenil}etinil)-1h-indol-1, 3-diil]dibutanoico.
DK2647619T3 (en) 2010-12-02 2015-03-02 Ono Pharmaceutical Co NEW RELATIONSHIP AND MEDICAL USE THEREOF
WO2012106382A1 (en) 2011-01-31 2012-08-09 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9353113B2 (en) 2011-03-18 2016-05-31 Ono Pharmaceutical Co., Ltd. Tetrahydrocarboline derivative
US9242977B2 (en) 2012-04-26 2016-01-26 Ono Pharmaceutical Co., Ltd. Trk-inhibiting compound
SG10201700808UA (en) 2013-02-19 2017-02-27 Ono Pharmaceutical Co Trk-INHIBITING COMPOUND
CA2919498C (en) 2013-07-31 2023-07-25 Windward Pharma, Inc. Aerosol nintedanib compounds and uses thereof
AU2015204558B2 (en) 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP3099672A4 (en) 2014-01-31 2017-09-20 ONO Pharmaceutical Co., Ltd. Fused imidazole compounds
JP7209963B2 (ja) 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
US20210100886A1 (en) 2017-03-30 2021-04-08 Sumitomo Dainippon Pharma Co., Ltd. Wt1 cancer antigen peptides and peptide conjugates comprising the peptides
JPWO2019049891A1 (ja) 2017-09-06 2020-10-15 小野薬品工業株式会社 Ｔｒｋ阻害剤とキナーゼ阻害剤の併用による癌治療方法
JP7388635B2 (ja) 2018-05-31 2023-11-29 小野薬品工業株式会社 免疫チェックポイント阻害薬の有効性判定バイオマーカー
TW202446772A (zh) 2018-10-11 2024-12-01 日商小野藥品工業股份有限公司 Ｓｔｉｎｇ促效化合物
KR20220041099A (ko) 2019-08-05 2022-03-31 오노 야꾸힝 고교 가부시키가이샤 면역 체크포인트 저해약의 유효성 판정 바이오마커
TW202134213A (zh) 2019-11-29 2021-09-16 日商小野藥品工業股份有限公司 具有水解磷脂酸受體作動活性之化合物及其醫藥用途
WO2021159077A1 (en) 2020-02-07 2021-08-12 Case Western Reserve University Compositions and methods for attenuating opioid induced cardio and/or respiratory depression
EP4134134A4 (en) 2020-04-10 2023-12-27 ONO Pharmaceutical Co., Ltd. STING AGONISTIC COMPOUND
EP4151227A4 (en) 2020-05-12 2025-01-15 Sumitomo Pharma Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2022251679A1 (en) 2021-05-27 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide radicals for use as antiviral treatment for coronavirus infection
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2222976A (en) * 1937-11-15 1940-11-26 Sharp & Dohme Inc Nasal drops
US2728495A (en) * 1951-04-19 1955-12-27 Little Inc A Liquid dispensing device and composition therefor

Also Published As

Publication number Publication date
GB830426A (en) 1960-03-16
US2868691A (en) 1959-01-13

Similar Documents

Publication Publication Date Title
AT12687B (Direct)
AT12969B (Direct)
AT13735B (Direct)
AT12729B (Direct)
DE7622443U1 (Direct)
AT13733B (Direct)
AT12663B (Direct)
AT11992B (Direct)
AT12007B (Direct)
AT12014B (Direct)
AT12070B (Direct)
AT12178B (Direct)
FR296702A (Direct)
AT12375B (Direct)
AT12417B (Direct)
AT12431B (Direct)
AT12637B (Direct)
AT12657B (Direct)
AT13281B (Direct)
AT14030B (Direct)
AT13314B (Direct)
AT13914B (Direct)
AT13376B (Direct)
AT13734B (Direct)
AT13447B (Direct)